北京因美未来

InmFuture is a Beijing-based biotechnology company that leverages artificial intelligence and structural biology to revolutionize drug discovery and protein design. Founded in 2021 by leading researchers from Tsinghua and Peking University, the company focuses on developing a proprietary platform that integrates deep learning with physics-based molecular dynamics. This platform is designed to tackle undruggable targets by predicting complex protein-protein interactions and designing high-affinity therapeutic candidates. InmFuture's pipeline includes both small molecule and protein-based programs primarily targeting oncology and immunological disorders. The company has successfully raised significant capital from top-tier investors such as GL Ventures and ZhenFund to advance its computational and experimental capabilities. By bridging the gap between digital prediction and wet-lab validation, InmFuture aims to significantly reduce the time and cost of bringing novel therapies to market.